Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumors with FGFR2 Alterations, Adult”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)Looking for participantsNCT06378593
What this trial is testing

3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Who this might be right for
Solid Tumors With FGFR2 Alterations, Adult
3H (Suzhou) Pharmaceuticals Co., Ltd. 130
Early research (Phase 1)Not Yet RecruitingNCT06287918
What this trial is testing

A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Who this might be right for
Solid Tumors With FGFR2 Alterations, Adult
3H (Suzhou) Pharmaceuticals Co., Ltd. 130
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Early research (Phase 1)Not Yet RecruitingNCT06800196
What this trial is testing

KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations

Who this might be right for
Solid Tumors with FGFR2 Alterations, Adult
KinoTeck Therapeutics Co., Ltd 151
Early research (Phase 1)Ended earlyNCT05242822
What this trial is testing

Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Who this might be right for
Solid Tumor, AdultIntrahepatic CholangiocarcinomaUrothelial Carcinoma
Kinnate Biopharma 54
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208